en · de · es · fr · pt
aod-9604-notes.peptides3626.com › Topic › Mechanism And Regulatory Status — Complete Guide

Mechanism And Regulatory Status — Complete Guide

By Editorial Desk · published 2026-07-17 · last reviewed 2026-08-01 · Topic

If you have been reading about lipolysis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.

Mechanism and Regulatory Status

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Measurement and Storage Practices

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Aod-9604 at a glance

PropertyValueNotes
Typical storage temperature-20 °CLyophilized peptide; protect from moisture and light.
Typical analytical methodHPLC and mass spectrometryUsed to confirm identity and estimate purity.
Common synonymsAOD9604; hGH 176-191Naming varies by supplier and publication.
Disulfide bondsOneAffects folded structure and stability.
Typical research purity≥95%Value depends on supplier and analytical method.

Research and Regulatory Status

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Related pages on this site

Regulation and Detection Context

Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.

Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.

Reference notes

During the Heian period (794 – 1185), the main use of cattle was for bullock carts. Cattle that excelled in this use were called sun-gyū (駿牛, swift bulls) and were regarded as excellent bulls. Owning such an excellent bull became a source of pride for the aristocrats of Japan at that time. The "Pictorial Record of Swift Bulls" (駿牛絵詞) which is believed to have been written around 1279, is said to be the world's oldest specialized book on bulls. In the same book, the names of 52 bulls are listed as swift bulls. At the time, the cattle from Iki Island in present-day Nagasaki Prefecture had the highest reputation as swift bulls, but they were temporarily destroyed by the Mongolian army during the Mongolian invasion, which killed them and used them as food. From the Kamakura period (1185–1333) to the Muromachi period (1336–1573), farming using cattle and horses became popular mainly in western Japan, contributing greatly to the development of agriculture. In a complaint by a farmer in 1423, describing the wrongdoing of a manor administrator, it mentions that the farmer owned cattle and used them for farming.

If pregnancy occurs, LH levels will decrease, and luteal function will instead be maintained by the action of hCG (human chorionic gonadotropin), a hormone very similar to LH but secreted from the new placenta. Gonadal steroids (estrogens and androgens) generally have negative feedback effects on GnRH-1 release at the level of the hypothalamus and at the gonadotropes, reducing their sensitivity to GnRH. Positive feedback by estrogens also occurs in the gonadal axis of female mammals and is responsible for the midcycle surge of LH that stimulates ovulation. Although estrogens inhibit kisspeptin (Kp) release from kiss1 neurons in the ARC, estrogens stimulate Kp release from the Kp neurons in the anteroventral periventricular nucleus (AVPV). As estrogens' levels gradually increase the positive effect predominates, leading to the LH surge. GABA-secreting neurons that innervate GnRH-1 neurons also can stimulate GnRH-1 release. These GABA neurons also possess ERs and may be responsible for the GnRH-1 surge. Part of the inhibitory action of endorphins on GnRH-1 release is through inhibition of these GABA neurons. Rupture of the ovarian follicle at ovulation causes a drastic reduction in estrogen synthesis and a marked increase in secretion of progesterone by the corpus luteum in the ovary, reinstating a predominantly negative feedback on hypothalamic secretion of GnRH-1.

== Biocompatibility == Generally PLGA is considered to be quite biocompatible. Its high biocompatibility results from its composition due to lactic and glycolic acid fermentation from sugars, making them eco-friendly and less reactive in the body. PLGA also degrades into non-toxic and non-reactive products that makes them quite useful for various medical and pharmaceutical applications. The biocompatibility of PLGA has been tested both in vivo and in vitro. The biocompatibility of this polymer is generally determined by the products that it degrades into, as well as the rate of degradation into degradation products. The way that PLGA degrades is by means of an enzyme known as esterase, which forms lactic acid and glycolic acid. These acids then undergo the Krebs Cycle to be degraded as carbon dioxide (CO2) and water (H2O). These byproducts then get removed from the body through cellular respiration and through the digestive process. While the byproducts usually do not accumulate in the body, there are instances where these byproducts (lactic and glycolic acid) can be dangerous to the body when accumulated in high local concentrations. There can also be small pieces of the polymers as the polymer degrades, causing an immune response by macrophages. These adverse effects can be reduced by using lower concentrations of the polymer, so that it gets naturally released throughout the body. Something else to consider regarding PLGA biocompatibility is the location at which the polymer is implanted or placed in the body.

== Selected bibliography == Banday Khalid M, Pasikanti KK, Chan EC, Singla R, Rao KV, Chauhan VS, Nanda RK. (July 2011). "Use of urine volatile organic compounds to discriminate tuberculosis patients from healthy subjects". Anal Chem. 83 (14): 5526–34. doi:10.1021/ac200265g. PMID 21619052.{{cite journal}}: CS1 maint: multiple names: authors list (link) Rao KV, Konar S, Gangadharan J, Vikas V, Sampath S (October 2015). "A pure non-gestational ovarian choriocarcinoma with delayed solitary brain metastases: Case report and review of the literature". J Neurosci Rural Pract. 6 (4): 578–81. doi:10.4103/0976-3147.169869. PMC 4692019. PMID 26752905. Jamwal SV, Mehrotra P, Singh A, Siddiqui Z, Basu A, Rao KV (March 2016). "Mycobacterial escape from macrophage phagosomes to the cytoplasm represents an alternate adaptation mechanism". Sci. Rep. 6 (23089) 23089. Bibcode:2016NatSR...623089J. doi:10.1038/srep23089. PMC 4793295. PMID 26980157. Ghosh AK1, Reddy BS, Yen YC, Cardenas E, Rao KV, Downs D, Huang X, Tang J, Mesecar AD (May 2016). "Design of Potent and Highly Selective Inhibitors for Human β-Secretase 2 (Memapsin 1), a Target for Type 2 Diabetes". Chem. Sci. 1 (7): 3117–3122. doi:10.1039/C5SC03718B. PMC 4916918. PMID 27347366.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)

Sources: en.wikipedia.org

Notes from published material

Keratoconus Global Award (2009) for his work on CXL technology. Carl Camras Award 2014 for translational research (Association for Research in Vision and Ophthalmology [ARVO]) The 2014 IIRSI Gold Medal for his efforts in introducing CXL into clinical ophthalmology Member of The Ophthalmologist Power List Top 100 (2014, 2016, 2018, 2020, and 2023) Casebeer Award (2014) of the International Society for Refractive Surgery. The 2016 El-Maghraby International Award for his contributions to ophthalmology The 2016 Gold Medal of SAMIR for his pioneering work on corneal cross-linking Elected as an honorary member of Hungary's SHIOL (Societas Hungarica Ad Implantandam Oculi Lenticulam) in 2016 Appointed FARVO (Fellow of ARVO) in 2019 Additionally, in 2012, Hafezi and his colleague, Dr. Olivier Richoz, won the University of Geneva's INNOGAP award for the development of a disposable medical device (the C-Eye device) for performing PACK-CXL. Hafezi is one of the most cited ophthalmologists of his generation, with a h index of 45 and a total more than 7,700 citations in the scientific literature.

Indium is a shiny silvery-white, highly ductile post-transition metal with a bright luster. It is so soft (Mohs hardness 1.2) that it can be cut with a knife or be bitten into by human teeth. Indium also leaves a visible line like a pencil when rubbed on paper. It is a member of group 13 on the periodic table and its properties are mostly intermediate between its vertical neighbors gallium and thallium. As with tin, a high-pitched cry is heard when indium is bent – a crackling sound due to crystal twinning. Like gallium, indium is able to wet glass and has a low melting point, 156.60 °C (313.88 °F); higher than its lighter homologue, gallium, but lower than its heavier homologue, thallium, and lower than tin.< The boiling point is 2072 °C (3762 °F), higher than that of thallium, but lower than gallium, conversely to the general trend of melting points, but similarly to the trends down the other post-transition metal groups because of the weakness of the metallic bonding with few electrons delocalized. The density of indium, 7.31 g/cm3, is also greater than gallium, but lower than thallium. Below the critical temperature, 3.41 K, indium becomes a superconductor. Indium crystallizes in the body-centered tetragonal crystal system in the space group I4/mmm (lattice parameters: a = 325 pm, c = 495 pm): this is a slightly distorted face-centered cubic structure, where each indium atom has four neighbours at 324 pm distance and eight neighbours slightly further (336 pm).

== Mechanism of action == Imipenem/cilastatin has the ability to kill a wide variety of bacteria. Imipenem is the active antibiotic agent and works by interfering with their ability to form cell walls, so the bacteria break up and die. Imipenem is rapidly degraded by the renal enzyme dehydropeptidase if administered alone (making it less effective); the metabolites can cause kidney damage. Imipenem is a broad-spectrum betalactam antibiotic used for severe bacterial infections caused by susceptible organisms. Because imipenem is rapidly inactivated by renal dehydropeptidase I, it is given in combination with cilastatin, a DHP-I inhibitor which increases half-life and tissue penetration of imipenem. Imipenem/cilastatin, like other carbapenems, binds to bacterial penicillin-binding proteins and interferes with bacterial cell wall integrity and synthesis. It has activity against many aerobic and anaerobic Gram-positive and Gram-negative organisms, including Staphylococcus aureus, Streptococcus pyogenes, S. agalactiae, S. viridans- group streptococci, Enterococcus faecalis, Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis and Peptostreptococcus species. Imipenem/cilastatin was approved for use in the United States in 1985. Imipenem/cilastatin is indicated for the treatment of severe or complicated skin, tissue, joint, respiratory tract, intra-abdominal, urinary tract and urogenital infections, but not meningitis (as it does not pass through the blood brain barrier), endocarditis, and sepsis due to susceptible organisms.

Zhang's tactics included propaganda, intelligence-gathering, and involvement in the opium trade, while Liu fought back with counter-propaganda and appointing loyalist magistrates who frustrated Zhang's work. Liu triumphed in 1942 when the 36th Division was moved to the Yunnanese front, and Zhang was transferred back to Chongqing in 1946. Zhang's presence was replaced by He Guoguang, but Liu continued frustrating Nationalist centralization attempts. In 1944 during Operation Ichi-Go, there was once again talk of moving the capital to Xichang, encouraged by American General Wedermeyer, but this was abandoned after the Japanese offensive stalled. In late 1942, Chiang ordered Liu and Ma Bufang of Qinghai to mobilize for a campaign against Tibet. Liu was suspicious of the Nationalist leader's motivations, dispatching his chief of staff Wu Peiying (伍培英) to Chongqing to plan for the invasion and negotiate with Chiang. According to Liu's 1990 biography, he had asked for a fully-equipped division of 10,000 troops, cavalry, and engineers; another division to maintain order, winter equipment, around 10,000 yaks, additional food supplies, and a truck route from Sichuan to Xikang. Liu also requested that he take sole command of these reinforcements. Later archival documents would confirm Liu's suspicions that the campaign was a plot; once Liu had mobilized his forces, Chiang was to send 30,000 men under his personal command into Xikang and depose Liu. Due to Liu's stalling tactics as well as Allied pressure, the campaign did not materialize.

=== American Cancer Society === Inhorn's ongoing interest in cervical cancer was the reason that he joined the American Cancer Society, Wisconsin Division, in 1967. He was Chair of the State Cancer Prevention Study II, and in 1986, he headed a demonstration project with a number of Wisconsin hospitals to determine the acceptance of offering low-cost mammography as a screening test for breast cancer. Inhorn served as President of the Wisconsin Division from 1970 to 1972, continuing on the board until 2010. He also served on the national American Cancer Society Board from 1982 to 1990.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for weight loss?

No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.

Why is AOD-9604 banned in sports?

The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.

Does AOD-9604 raise growth hormone levels?

It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.

How is AOD-9604 typically analyzed?

Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.

Network